endocannabinoid in ocular fluid of patients with or without diabetes

  • Research type

    Research Study

  • Full title

    Endocannabinoid in ocular fluid of patients with or without diabetes and other retinal disorders

  • IRAS ID

    149096

  • Contact name

    I Idris

  • Contact email

    iskandar.idris@nottingham.ac.uk

  • Sponsor organisation

    University of Nottingham

  • Duration of Study in the UK

    1 years, 6 months, 3 days

  • Research summary

    The main purpose of the study is to observe the effects of a naturally occurring series of substances in theeyes, collectively known as the endocannabinoid, and its association with various types of eye related diseases in people with or without diabetes. We know that is a diseased eye, especially where there is reduced amount of oxygen in the eyes, as in people with diabetes, various substances are produced that puts more strain on the blood circulation in the eyes. Despite this, there remains very limited treatment available for the treatment of patients with diabetic eye disease. Markers of endocannabinoid activities have recently been shown to be altered in the eye tissues of people with diabetes. What we don’t know is which types of endocannabinoid substances are affected or altered in diabetic eye disease and whether it is associated with severity of the disease. By measuring the amount of endocannabinoids produced in the eye fluid, we will gain some understanding on the role of these substances in the development of diabetic eye disease.

  • REC name

    North East - York Research Ethics Committee

  • REC reference

    15/NE/0031

  • Date of REC Opinion

    22 Jan 2015

  • REC opinion

    Favourable Opinion